120157-97-3

Usage

Uses

Used in Pharmaceutical Industry:
N-BOC-2-(4-BROMO-PHENYL)-ETHYLAMINE is used as a reagent for the preparation of second-generation dual inhibitors of Cysteine protease falcipain-3 (FP-3) and Plasmodium falciparum dihydrofolate reductase (PfDHFR). These enzymes are essential for the survival and proliferation of malarial parasites, making them attractive targets for the development of new antimalarial drugs. N-BOC-2-(4-BROMO-PHENYL)-ETHYLAMINE's role in the synthesis of these inhibitors highlights its potential in contributing to the fight against malaria.
Additionally, N-BOC-2-(4-BROMO-PHENYL)-ETHYLAMINE is used in the preparation of indole-2-carboxamides, which are novel allosteric modulators of the cannabinoid (CB-1) receptor. These modulators have potential applications in the treatment of various disorders, including obesity, type 2 diabetes, and neurodegenerative diseases. N-BOC-2-(4-BROMO-PHENYL)-ETHYLAMINE's involvement in the synthesis of these modulators underscores its importance in the development of innovative therapeutic agents for a range of medical conditions.

InChI:InChI=1/C13H18BrNO2/c1-13(2,3)17-12(16)15-9-8-10-4-6-11(14)7-5-10/h4-7H,8-9H2,1-3H3,(H,15,16)

Upstream product

• 16532-79-9 4-Bromophenylacetonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 73918-56-6 4-Bromophenethylamine 
• 144-55-8 sodium hydrogencarbonate 
• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 41840-28-2 S-tert-butoxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine 

Downstream Products

• 120158-10-3 [2-(4-Bromo-phenyl)-acetyl]-carbamic acid tert-butyl ester 
• 360792-43-4 tert-butyl N-[2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]carbamate 
• 1055276-57-7 C₂₁H₂₈N₂O₃ 
• 1056950-87-8 tert-butyl 2-[4-(1H-imidazol-1-yl)phenyl]ethylcarbamate 
• 172348-86-6 tert-butyl N-[2-(4-cyanophenyl)ethyl]carbamate 
• 132690-91-6 4-[2-(tert-butyloxycarbonylamino)ethyl]benzoic acid 
• 1418212-16-4 tert-butyl 4-(pyridin-2-yl)phenethylcarbamate 
• 1191063-30-5 tert-butyl N-[2-(4-bromophenyl)ethyl]-N-(methyl)carbamate 
• 1189922-22-2 2-(4'-fluoro-[1,1'-biphenyl]-4-yl)ethan-1-amine hydrochloride 

Relevant academic research and scientific papers

Studies toward the development of new silicon-containing building blocks for the direct 18F-labeling of peptides

Silicon-containing prosthetic groups have been conjugated to peptides to allow for a single-step labeling with 18F radioisotope. The fairly lipophilic di-tert-butylphenylsilane building block contributes unfavorably to the pharmacokinetic profile of bombesin conjugates. In this article, theoretical and experimental studies toward the development of more hydrophilic silicon-based building blocks are presented. Density functional theory calculations were used to predict the hydrolytic stability of di-tert-butylfluorosilanes 2-23 with the aim to improve the in vivo properties of 18F-labeled silicon-containing biomolecules. As a further step toward improving the pharmacokinetic profile, hydrophilic linkers were introduced between the lipophilic di-tert-butylphenylsilane building block and the bombesin congeners. Increased tumor uptake was shown with two of these peptides in xenograft-bearing mice using positron emission tomography and biodistribution studies. The introduction of a hydrophilic linker is thus a viable approach to improve the tumor uptake of 18F-labeled silicon-bombesin conjugates.

H2O2/Peroxynitrite-Activated Hydroxamic Acid HDAC Inhibitor Prodrugs Show Antileukemic Activities against AML Cells

Occurrence of acute myeloid leukemia (AML) results in abundant endogenous reactive oxygen species (ROS)/reactive nitrogen species (RNS) in AML cells and in disease-relevant microenvironments. Histone deacetylase inhibitor (HDACi) prodrug approach was designed accordingly by masking the hydroxamic acid zinc binding group with hydrogen peroxide (H2O2)/peroxynitrite (PNT)-sensitive, self-immolative aryl boronic acid moiety. Model prodrugs 5-82 and 5-23 were activated in AML cells to release cytotoxic HDACis, evidenced by inducing acetylation markers and reducing viability of AML cells. Intracellular activation and antileukemic activities of prodrug were increased or decreased by ROS/PNT inducers and scavengers, respectively. Prodrugs 5-82 and 5-23 also enhanced the potency of chemotherapy drug cytarabine, supporting the potentials of this prodrug class in combinatorial treatment.

Direct Access to Primary Amines from Alkenes by Selective Metal-Free Hydroamination

Direct and selective synthesis of primary amines from easily available precursors is attractive yet challenging. Herein, we report the rapid synthesis of primary amines from alkenes via metal-free regioselective hydroamination at room temperature. Ammonium carbonate was used as ammonia surrogate for the first time, allowing for efficient conversion of terminal and internal alkenes into linear, α-branched, and α-tertiary primary amines under mild conditions. This method provides a straightforward and powerful approach to a wide spectrum of advanced, highly functionalized primary amines which are of particular interest in pharmaceutical chemistry and other areas.

Optimization and Evaluation of Novel Antifungal Agents for the Treatment of Fungal Infection

Due to the increased morbidity and mortality by fungal infections and the emergence of severe antifungal resistance, there is an urgent need for new antifungal agents. Here, we screened for antifungal activity in our in-house library through the minimum inhibitory concentration test and derived two hit compounds with moderate antifungal activities. The hit compounds' antifungal activities and drug-like properties were optimized by substituting various aryl ring, alkyl chain, and methyl groups. Among the optimized compounds, 22h was the most promising candidate with good drug-like properties and exhibited potent fast-acting fungicidal antifungal effects against various fungal pathogens and synergistic antifungal activities with some known antifungal drugs. Additionally, 22h was further confirmed to disturb fungal cell wall integrity by activating multiple cell wall integrity pathways. Furthermore, 22h exerted significant antifungal efficacy in both the subcutaneous infection mouse model and ex vivo human nail infection model.

SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS

Disclosed are 7-phenyl-2-aminoquinoline compounds that are shown to inhibit the biological activity of neuronal nitric oxide synthases (nNOSs). Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds and

Amphiphilic Polymeric Nanoparticles for Photoredox Catalysis in Water

Photoredox catalysis has recently emerged as a powerful synthesis tool in organic and polymer chemistry. In contrast to the great achievements realized in organic solvents, performing photocatalytic processes efficiently in aqueous media encounters several challenges. Here, it is presented how amphiphilic single-chain polymeric nanoparticles (SCPNs) can be utilized as small reactors to conduct light-driven chemical reactions in water. By incorporating a phenothiazine (PTH) catalyst into the polymeric scaffold, metal-free reduction and C?C cross-coupling reactions can be carried out upon exposure to UV light under ambient conditions. The versatility of this approach is underlined by a large substrate scope, tolerance towards oxygen, and excellent recyclability. This approach thereby contributes to a sustainable and green way of implementing photoredox catalysis.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

CHEMICAL COMPOUNDS

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.

P300/CBP HAT INHIBITORS

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).